Sunday, 12 July 2020


Glenmark receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%

15 March 2019 | News

It is a generic version of BenzaClin® Gel, 1%|5%, of Valeant Bermuda

Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin® Gel, 1%|5%, of Valeant Bermuda.

According to IQVIATM sales data for the 12 month period ending January 2019, the BenzaClin® Gel, 1%|5% market2 achieved annual sales of approximately $99.4 million.

Glenmark’s current portfolio consists of 151 products authorized for distribution in the U.S. marketplace and 53 ANDA’s pending approval with the U.S. FDA.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account